-
LGK-974: A PORCN Inhibitor Across Wnt Models
2026-09-15
Explore how LGK-974, a potent PORCN inhibitor, can be used to interrogate Wnt secretion, pathway dependence, and model-specific responses. This article connects cancer pharmacology with emerging evidence in sclerosteosis while emphasizing assay design and translational limitations.
-
Flavopiridol: Reliable CDK Assay Workflows
2026-09-15
This scenario-based guide explains how Flavopiridol, SKU A3417, can support interpretable cell-cycle, proliferation, and cytotoxicity experiments. It connects product specifications with practical controls, ER-stress confounding, protocol design, data interpretation, and evidence-based product selection.
-
From CCK-8 Signal to PANoptosis Insight
2026-09-14
A mechanistic and translational guide to using Cell Counting Kit-8 (CCK-8) in endoplasmic reticulum stress and PANoptosis research, with practical assay design, orthogonal validation strategies, and guidance for interpreting viability data beyond a conventional product page.
-
MHY1485: A Mechanistic Guide to mTOR–Autophagy Assays
2026-09-14
Explore how MHY1485 functions as an mTOR activator for mechanistic autophagy assays, with practical guidance for interpreting LC3-II accumulation, pathway controls, and model-specific outcomes. This guide connects the LINC01278 study with rigorous experimental design and ovarian follicle development research.
-
Penicillin G Sodium: Culture Workflow & Controls
2026-09-13
Build more reproducible cell-culture and antimicrobial workflows with Penicillin G Sodium while keeping antibiotic exposure separate from experimental biology. This guide combines mechanism, practical preparation, melanoma-assay controls, and troubleshooting for contamination, stability, and endpoint interference.
-
β-Pseudouridine: An Assay-First RNA Strategy
2026-09-12
β-Pseudouridine is the C-glycoside isomer of uridine with important consequences for RNA structure and translational fidelity. This assay-first guide separates nucleoside chemistry from RNA-platform effects and translates recent influenza vaccine findings into better experimental decisions.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-09-12
The reference study develops a nonviral, localized tumor-suppressor replacement strategy using chemically modified p21 mRNA in lipid nanoparticles for bladder cancer. Its preclinical data connect bladder-restricted expression with cell-cycle inhibition, DNA-damage signaling, apoptosis, and tumor suppression, while also highlighting the translational limits of moving from an orthotopic mouse model to clinical therapy.
-
DMXAA in Nuclear-Targeted Nanorods for STING Immunity
2026-09-11
The reference study develops PFPD, self-assembled peptide nanorods that co-deliver DMXAA and a photosensitizer to tumor-cell nuclei. Light-triggered nuclear DNA damage supplies endogenous immunostimulatory DNA, while DMXAA activates STING, producing stronger innate immune responses and suppressing lung metastatic tumors in experimental models.
-
Gefitinib as an EGFR Signaling Probe
2026-09-11
Explore how Gefitinib (ZD1839) can function as a causal EGFR signaling probe in cancer and blue-light skin-barrier assays. This guide connects molecular pharmacology, pathway-resolved readouts, and practical experimental design while clearly separating established evidence from translational hypotheses.
-
TRIM21–ERK1/2 Signaling in Pituitary Adenomas
2026-09-10
The reference study identifies TRIM21 as a regulator of ERK1/2 signaling, pituitary adenoma cell proliferation, and resistance to dopamine-directed therapy. Its combination of CRISPR screening, biochemical validation, animal models, and NanoBiT-based drug screening nominates TRIM21 suppression as a mechanistically testable treatment strategy.
-
Mechanisms of Cell Death in Heart Disease
2026-09-10
This review reframes necrosis as potentially regulated rather than uniformly passive, placing apoptosis, necrosis, and autophagy within interconnected death-signaling networks relevant to myocardial infarction and heart failure. Its practical value lies in showing why morphology, ATP status, membrane integrity, and pathway-specific perturbations should be interpreted together when designing cell-death studies.
-
MK-5108 (VX-689): Assay Workflows
2026-09-09
A scenario-driven guide to using MK-5108 (VX-689), SKU A4120, in Aurora-A-focused viability, proliferation, and cytotoxicity studies. It connects biochemical selectivity, formulation handling, dose-response design, retinoblastoma evidence, and practical vendor selection to improve assay interpretability.
-
Spermine as a Mechanistic Cell Biology Probe
2026-09-09
Spermine is an endogenous polyamine that links ion channel regulation with experimental analysis of membrane biology. This article explains how its defined inward rectifier activity can sharpen assay design while clarifying what the CLCC1 herpesvirus nuclear-egress study does—and does not—demonstrate.
-
Go 6983: Pan-PKC Inhibitor Research Guide
2026-09-08
Go 6983 is a pan-PKC inhibitor used to dissect isoform-dependent PKC signaling in cancer, EMT, and cellular assays. Its strongest reported biochemical activity is against PKCα, PKCβ, PKCγ, and PKCδ, while PKCμ is substantially less sensitive according to product information.
-
Resiquimod (R-848): Designing Better Ablation Assays
2026-09-08
Resiquimod (R-848) is a dual TLR7/8 agonist that can reveal how innate immune response modulation shapes post-ablation tumor biology. This guide presents a spatial, time-resolved framework for connecting TLR signaling, thermal injury, drug release, and translational assay design.